Peter C. Gøtzsche, MD is a Danish medical researcher, and leader of the Nordic Cochrane Center at Rigshospitalet in Copenhagen, Denmark

For more informative videos and free information visit http:drmcdougall.com
Peter C. Gøtzsche, MD is a Danish medical researcher, and leader of the Nordic Cochrane Center at Rigshospitalet in Copenhagen, Denmark. He has written numerous reviews within the Cochrane collaboration.
Dr.Gøtzsche has been critical of screening for breast cancer using mammography, arguing that it cannot be justified; His critique stems from a meta-analysis he did on mammography screening studies and published as Is screening for breast cancer with mammography justifiable? in The Lancet in 2000. In it he discarded 6 out of 8 studies arguing their randomization was inadequate.
In 2006 a paper by Gøtzsche on mammography screening was electronically published in the European Journal of Cancer ahead of print. The journal later removed the paper completely from the journal website without any formal retraction. The paper was later published in Danish Medical Bulletin with a short note from the editor, and Gøtzsche and his coauthors commented on the unilateral retraction that the authors were not involved in.
In 2012 his book Mammography Screening: Truth, Lies and Controversy was published. In 2013 his book Deadly Medicines and Organized Crime: How Big Pharma has Corrupted Healthcare was published.

The book is comprehensive, with worldwide examples across many categories of drugs of how the pharmaceutical industry operates. It describes the history of the pharmaceutical industry well, and is current, with references from 2013. The comprehensive attack on the largest drug companies is scathing, and it provokes physicians to be more cautious about prescribing. But most important, it shows us that evidence-based medicine and guidelines have been hijacked, as the evidence base has been systematically distorted.11,12 Consequently, we must rethink which evidence and which recommendations we should use to help our patients. A helpful start is the Public Citizen approach of not using any new drug until it is 7 years old.13

Authors’ conclusions:
The design and reporting of safety outcomes in MMR vaccine studies, both pre- and post-marketing, are largely inadequate. The evidence of adverse events following immunisation with the MMR vaccine cannot be separated from its role in preventing the target diseases.